Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Virol. 2005 Jul;33(3):188-93. Epub 2004 Dec 10.

Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.

Author information

  • 1Division of Clinical Retrovirology and Infectious Diseases, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan. shuzo@kaiju.medic.kumamoto-u.ac.jp

Abstract

OBJECTIVE:

In order to evaluate long-term toxicity of Combivir, we retrospectively reviewed clinical records of HIV-1 infected cases under treatment with Combivir-containing regimen and we analyzed the clinical data compared to other NRTIs-containing regimens.

STUDY DESIGN:

A total of 55 patients who were on Combivir and 39 on a control regimen were examined.

RESULTS:

After starting treatment with Combivir-containing regimens viral load and CD4(+) T-cell count improved as well as the control group. Rates of adverse events in Combivir group and ZDV (400 mg/day) + 3TC group were 50.9% (28/55) and 60% (12/20), respectively. Some of these Japanese patients who started Combivir regimen as a first-line HAART (primary Combivir group) showed some decrease in hemoglobin levels or neutrophil counts within 6 months. However, a significant recovery of these indices of hematological toxicities occurred in patients who continued the regimen for 18-24 months.

CONCLUSION:

Our findings suggest that the safety of 600 mg of ZDV is similar to 400 mg/day of ZDV and the existence of mechanisms that compensate for anemia and for the neutropenia associated with long-term use of Combivir.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk